The cover image is based on the article Detecting PI3K and TP53 Pathway Disruptions in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients by Cecilia Monge et al., https://doi.org/10.1002/cam4.70791.

ACE2 and TMPRSS2 not only mediate SARS-CoV-2 infection may also be involved in cancer progression (such as affecting tumor proliferation, matastasis or immune infiltration), and they can be used as targets to treat cancer patients infected with SARS-CoV-2.

Patients with cancer and their families have important lessons to teach oncology clinicians about how to improve care. In this study, we asked pediatric patients and parents to reflect on how their doctors talked about prognosis to help us identify ways to improve this process. We learned that when patients and parents feel that the doctor did not discuss prognosis in a good way, it was usually due to (1) insufficient information, (2) overwhelming or contradictory information, and (3) absence of person-centered connection. These findings will help guide communication training and future research to improve communication.

Enhancements in the creation of animal models that most accurately represent the aggressive types of pancreatic neuroendocrine neoplasms are necessary to create therapeutic protocols that combine immunotherapies with other medication classes to help patients with metastatic disease recover or respond to treatment more durably. Tumor microenvironment is thought to be essential to immunotherapy's effectiveness; nonetheless, assessing the immune microenvironment and its clinical ramifications remains difficult, particularly in neuroendocrine neoplasms.

This real-world study conducted with SEER-Medicare data of patients aged 65 years or older with de novo HR+/HER2– metastatic breast cancer found that treatment with palbociclib in combination with an aromatase inhibitor (AI) was associated with significantly prolonged overall survival compared with AI alone.

Our study examines disparities in enrollment for pediatric oncology clinical trials, focusing on pediatric patients with hepatoblastoma and Wilms tumor. We found few disparities in trial enrollment, though young age at diagnosis was a statistically significant predictor for Wilms tumor cases.

This study was designed to evaluate the use of NEPA (netupitant/palonosetron) plus dexamethasone with or without olanzapine for the prevention of CINV in the second cycle of chemotherapy for patients receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) who developed breakthrough CINV in their first cycle despite guideline-directed prophylactic antiemetics. Of the 227 patients enrolled in Cycle 1, 100 patients (n = 37 HEC, 63 MEC) experienced breakthrough CINV and received the NEPA-based treatments in Cycle 2. The complete response (no emesis/no rescue use) rates during the overall (0–120 h) phase were 76% and 79% in the HEC and MEC groups, respectively, suggesting that NEPA with or without olanzapine is an effective approach for CINV prevention for patients receiving HEC or MEC who develop breakthrough CINV after their first course of chemotherapy.

This retrospective study aimed to assess the impact of adjusting serum creatinine (SCr) values when determining carboplatin (CBDCA) doses in ovarian cancer chemotherapy. Patients treated with CBDCA + paclitaxel (TC) were categorized based on the regimen they received (dose-dense TC or tri-weekly TC) and whether or not their SCr levels were adjusted. Our findings suggest that in patients receiving dose-dense TC, but not in those receiving tri-weekly TC, adjusting SCr did not compromise the dose intensity of total CBDCA and may contribute to maintaining dose intensity, highlighting potential benefits in reducing treatment modification and adverse events.

Culturally and linguistically diverse populations have lower engagement and experience multiple challenges accessing breast screening services. Specific culturally appropriate, tailored, multi-component strategies are necessary to improve engagement in breast screening services for these populations.

This study identifies distinct PI3K and TP53 pathway disruptions in early-onset colorectal cancer among Hispanic/Latino patients, with findings suggesting a higher prevalence of PI3K alterations and potential differences in outcomes associated with TP53 disruptions compared to non-Hispanic Whites. While these results provide valuable insights into potential molecular drivers of disparities, further research is needed to fully understand their clinical implications. These findings may suggest new directions for precision medicine approaches aimed at addressing cancer health disparities and improving equity in colorectal cancer care.

This retrospective cohort study followed up women who underwent CKC and had negative margins on conization for up to 10 years. The risk of residual or recurrent HSIL+ was higher in patients with HPV persistence for 12 months compared with HPV positive at 6 months after CKC. In patients with negative margins, extending the follow-up interval to 12 months may reduce the number of HPV tests and colposcopy referral rates while maintaining HSIL+ detection.

In patients with recurrent or metastatic adenoid cystic carcinoma (ACC) combination nivolumab with ipilimumab resulted in moderate disease control. Patients with non-ACC salivary gland carcinomas did not see responses to treatment.

For hematologic malignancies, the infectious diseases mortality (IDM) rates were highest in the first 2 months after diagnosis and gradually declined thereafter. It is extremely important to identify patients at high risk of IDM and provide timely intervention to prevent early death from infections and improve prognosis.

Cancer accumulation and anticancer activity of “CROX (cluster regulation of RUNX)” PIP in HER2-positive gastric cancer evaluated by chicken egg cancer model.